A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
- 1 October 2009
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 76 (7), 705-716
- https://doi.org/10.1038/ki.2009.246
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontinKidney International, 2009
- The emerging role of phosphate in vascular calcificationKidney International, 2009
- The vitamin D deficiency pandemic and consequences for nonskeletal health: Mechanisms of actionMolecular Aspects of Medicine, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Effect of Frequent Nocturnal Hemodialysis vs Conventional Hemodialysis on Left Ventricular Mass and Quality of LifeJAMA, 2007
- Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in menBone, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care OrganizationArchives of Internal Medicine, 2004
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989